<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00518193</url>
  </required_header>
  <id_info>
    <org_study_id>ERBUS</org_study_id>
    <nct_id>NCT00518193</nct_id>
  </id_info>
  <brief_title>Phase II Study , Association of Cisplatine Topotecan and Cetuximab in Patients Whith Late or in Progress Epithelial Cancer of the Cervix</brief_title>
  <acronym>ERBUS</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy of chimiotherapy in cervix epithelial cancer is low even with the association
      cisplatine - topotecan .

      News thérapeutics are needed in the goal of increase the survival and quality of life in
      patients with cervix cancer.

      Cetuximab has shown the potentialisation on the efficacy of cisplatine and irinotecan.

      Cisplatine and topotecan have shown an efficacy in cervix cancer. Cetuximab is well tolerate.
      Many clinical trials shown the faisability of the association of cetuximab and cisplatine in
      cancer.

      Many clinical trials have shown the faisability of association of cetuximab and irinotecan in
      colorectals metastatiques cancers .
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    high rate of medullar aplasia with infectious troubles.
  </why_stopped>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>responses rate regarding the RECIST criteria.</measure>
    <time_frame>up to progression</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life, free interval, safety.</measure>
    <time_frame>up to progression</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">44</enrollment>
  <condition>Cervix Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ERBITUX</intervention_name>
    <description>400 mg/m² 2h injection at week 1, then 250 mg/m² in one hour injection the following weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  More than 18 years old.

          -  Epidermoïde carcinoma or adenocarcinoma of the cervix, hystologic proved

          -  Patientes in a late stage or with progresive desease.

          -  One mesurable lesion in irradiated zone.

          -  Patient who have already treated radio-chimiothérapy with platine should have a 6
             month free interval.

          -  Index status of ECOG (&quot; Eastern Cooperative Oncology Group &quot;)less than 2.

          -  Good biologicals and hematologicals fonctions:

          -  Neutrophiles noless than 1,5.109/L.

          -  Platelets nolss than 100.109/L.

          -  Total bilirubin no more than 1,5 time the normal superior range.

          -  Transaminases no mote than 3 x Time NSR

          -  Creatinine clairance Cockroft) more than 50 mL/min .

          -  Inform consent signed.

        Exclusion Criteria:

          -  Previous cytotoxic traitement exept radio-chaemiotherapy of the pelvis cerebrals
             metastasis.

          -  Other cancer in the last 5 years exept treated BCC.

          -  Dermatologic desease.

          -  Crohn desease or Hemorragic rectal-Colitis.

          -  Neuropathy.

          -  Psychologic disorder.

          -  Social troubles.

          -  Pregnant women.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pr KURTZ Jean Emmanuel</last_name>
    <role>Principal Investigator</role>
    <affiliation>STRASBOURG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRLC Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital HOTEL DIEU</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncologie, Hôtel-Dieu, 1 place du parvis Notre-Dame</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Claudius Régaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.arcagy.org</url>
  </link>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2007</study_first_submitted>
  <study_first_submitted_qc>August 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2007</study_first_posted>
  <last_update_submitted>June 29, 2011</last_update_submitted>
  <last_update_submitted_qc>June 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2011</last_update_posted>
  <responsible_party>
    <name_title>Frédéric MARMION</name_title>
    <organization>ARCAGY-GINECO</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

